Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer

Launched by MAYO CLINIC · May 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging technology called photon counting detector CT (PCD-CT) to see if it can better determine the growth of rectal cancer compared to the current standard method, which is MRI. The goal is to find out if PCD-CT can help doctors manage patients with rectal cancer more effectively.

To take part in this study, participants need to be adults aged 18 to 99 who have been diagnosed with rectal cancer and are scheduled for imaging tests. They should have a tumor that is at least 2 cm in size and be willing to sign consent forms. Participants will undergo both the new PCD-CT scan and the traditional MRI to compare the results. It's important to note that individuals with certain medical conditions, such as severe kidney issues or specific types of cancer, may not be eligible. If you are considering joining this trial, you will be supported throughout the process and receive thorough information about what to expect.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients 18 to 99 years of age
• • Patients with proven rectal cancer clinically referred for staging pelvic MRI and contrast-enhanced CT of the abdomen and pelvis (for evaluation of liver and peritoneal disease)
• • Endoscopic or imaging report that tumor is 2 cm or larger
• • Patients who are able and willing to sign the informed consent
• • Negative pregnancy test if subject is of child-bearing age (females of child-bearing potential will be screened for pregnancy using a urine pregnancy test, which will be administered by the unit study coordinator at no cost to the patient)
• Exclusion Criteria:
• • Minors less than 18 years old
• • Known mucinous adenocarcinoma (may not enhance well)
• • Patient unable to provide written informed consent
• • Pregnancy
• • estimated Glomerular Filtration Rate (eGFR) ≤ 60
• • History of prior moderate or severe contrast reaction including unresponsiveness, severe respiratory distress, convulsions, arrhythmia, cardiopulmonary distress, progressive angioedema, laryngeal edema, dyspnea, bronchospasm, symptomatic tachycardia, symptomatic bradycardia, hypotension, hypertensive crisis
• • Any history of premedication prior to iodinated contrast
• • Hip replacement/prosthesis
• • Patients that consent to participation but do not undergo their clinically indicated MRI scanning for any reason (e.g., bad IV, infiltration, reaction, change in indication)